Investors sold shares of Becton Dickinson and Co (NYSE:BDX) on strength during trading hours on Thursday after an insider sold shares in the company. $77.93 million flowed into the stock on the tick-up and $124.23 million flowed out of the stock on the tick-down, for a money net flow of $46.30 million out of the stock. Of all equities tracked, Becton Dickinson and had the 17th highest net out-flow for the day. Becton Dickinson and traded up $7.62 for the day and closed at $244.48Specifically, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total value of $1,257,606.04. Following the sale, the executive vice president now owns 13,318 shares of the company’s stock, valued at approximately $3,227,750.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.
A number of research firms recently issued reports on BDX. Morgan Stanley upped their target price on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Wells Fargo & Co upped their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Citigroup upped their target price on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, KeyCorp reaffirmed a “buy” rating and issued a $264.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $254.07.
The company has a market capitalization of $64.40 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 1.44 and a beta of 1.19. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81.
Several institutional investors have recently modified their holdings of BDX. Fundsmith Equity Fund L.P. acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth $894,775,000. FMR LLC increased its holdings in shares of Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock worth $4,069,559,000 after buying an additional 2,049,874 shares during the last quarter. Charles Schwab Investment Advisory Inc. acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth $291,167,000. Vontobel Asset Management Inc. increased its holdings in shares of Becton Dickinson and by 823.0% during the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock worth $250,205,000 after buying an additional 904,097 shares during the last quarter. Finally, Cornerstone Wealth Management LLC increased its holdings in shares of Becton Dickinson and by 233.6% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock worth $3,286,000 after buying an additional 453,623 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Investors Sell Becton Dickinson and (BDX) on Strength After Insider Selling” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/11/08/investors-sell-becton-dickinson-and-bdx-on-strength-after-insider-selling.html.
About Becton Dickinson and (NYSE:BDX)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Article: How to invest in a bear market
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.